NVIDIA Data: 70% of Healthcare Firms Now Deploying AI Tech

Healthcare AI has shifted from experimental technology to a core business strategy delivering tangible financial returns for C-suite executives.

According to NVIDIA's latest State of AI in Healthcare and Life Sciences survey of more than 600 industry professionals, 85% of management respondents report AI has increased annual revenue, while 80% cite reduced operational costs.

Perhaps most significantly for business leaders, 44% state that AI increased revenue by more than 10%, with smaller companies seeing even greater impact at 56%. With 70% of organisations now actively using AI – representing significant year-over-year growth – and 69% deploying generative AI and large language models, the technology has moved beyond pilot programmes into production environments that affect bottom-line performance.

The shift from experimental deployments to production-grade implementations marks a maturation point for healthcare AI. Organisations are no longer asking whether AI can deliver value, but rather how to scale proven applications across their operations.

AI implementation across industry segments

Adoption patterns reveal that AI deployment spans every major healthcare segment. Digital healthcare leads at 78% active use, followed by pharmaceutical and biotech at 74% and medical technology at 70%. Even traditionally conservative sectors are accelerating adoption, with payers and providers showing a 13% year-over-year increase, rising from 43% to 56%.

"Over the next 12 to 18 months, the most visible and scalable impact of AI will come from logistics and administrative streamlining," says John Nosta, President of NostaLab, a healthcare think tank. "That's where adoption curves are already steep, scheduling, documentation, coding, utilisation management and care coordination."

The survey finds that predictive and data analytics remain foundational, with 65% of organisations using AI for data analytics and data science. Clinical integration is advancing, with 42% citing clinical decision support as their top AI use case, while 38% report using AI for medical imaging and 38% for administrative workflow optimisation.

These deployment patterns suggest that organisations are pursuing parallel tracks: leveraging AI for both immediate operational gains and longer-term clinical transformation. The breadth of adoption across segments indicates that competitive pressure is driving investment decisions as much as internal ROI calculations.

Targeted applications generate ROI

For executives evaluating AI investment priorities, the data suggests that focused, use case-specific deployments generate stronger returns than broad initiatives. In the medical technology segment, 57% report achieving ROI from AI in medical imaging. Similarly, 46% of pharmaceutical and biotech organisations report ROI from AI in drug discovery and development.

"Scaling generative AI in healthcare starts with focusing on real clinical and operational problems, rather than the technology itself," says Dr Annabelle Painter, Clinical AI Strategy Lead at Visiba UK. "The organisations seeing impact are those that embed AI into existing workflows instead of layering AI on top as a separate tool."

From a cost perspective, 35% of all respondents and 44% of small companies report cost reductions greater than 10%, suggesting AI's financial impact extends beyond revenue growth to operational efficiency gains.

The concentration of ROI in specific application areas provides a roadmap for executives: medical imaging for medtech companies, drug discovery for pharma and biotech, and administrative optimisation across the board. This targeted approach reduces implementation risk while accelerating time to value.

Infrastructure investment and future outlook

Recent developments show the emergence of agentic AI – advanced systems capable of autonomous reasoning and task execution. NVIDIA's data shows that 47% of respondents are actively using or assessing AI agents, with top use cases including knowledge management and retrieval at 46%, literature review and analysis at 38% and internal process optimisation at 37%.

Strong financial returns are driving continued investment. The survey shows that 85% of respondents expect their AI budgets to increase in 2026, with nearly half anticipating growth exceeding 10%. Spending priorities are shifting towards scaling proven solutions, with 47% planning to focus on optimising AI workflows and production cycles, compared to 34% in 2025.

Despite momentum, challenges remain that executives must navigate. Smaller organisations report budget constraints at 40% and insufficient data for training at 33% as top barriers, while larger enterprises cite data-related concerns such as privacy and security at 39% and regulatory and ethical issues at 37%.

Overall, the data indicates that AI in healthcare and life sciences has moved beyond experimentation into a phase of measurable business impact, positioning industry leaders who invest strategically for competitive advantage in the years ahead.